<DOC>
	<DOCNO>NCT02742051</DOCNO>
	<brief_summary>This open , randomized pilot feasibility trial evaluate feasibility effect neoadjuvant everolimus plus letrozole versus neoadjuvant fluorouracil , epirubicin plus cyclophosphamide ( FEC ) treat postmenopausal woman ER-positive , HER2-negative breast cancer . Forty postmenopausal stage M0 , ER-positive , HER2-negative invasive breast cancer woman primary tumor &gt; 2cm image axillary lymph node &gt; 2cm image randomly ( 1:1 ) enrol receive neoadjuvant everolimus plus letrozole 18 week neoadjuvant FEC 6 cycle surgery . The primary objective determine feasibility neoadjuvant everolimus plus letrozole postmenopausal patient ER-positive , HER2-negative breast cancer , compare response rate clinical palpation . Secondary aim compare ultrasound response rate , pathological complete response ( pCR ) rate , breast-conserving surgery rate , toxicity , change percentages peripheral blood CD8+ T cell , T helper cell ( Th ) , regulatory T cell ( Treg ) , NK cell ( pre- versus post- neoadjuvant therapy ) .</brief_summary>
	<brief_title>A Trial Neoadjuvant Everolimus Plus Letrozole Versus FEC Women With ER-positive , HER2-negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>The patient sign write informed consent The patient present nonmetastatic unilateral invasive ERpositive , HER2negative breast cancer primary breast tumor &gt; 2cm image axillary lymph node &gt; 2cm imaging . Postmenopausal woman age less 70 year old . The patient history hormone therapy , chemotherapy , breast cancer surgery radiotherapy . The patient normal cardiac function echocardiography . The patient ' ECOG score ≤2 . The patient swallow pill . The result patient ' blood test follow : Hb≥90g/L ; WBC≥4E+9/L ; Plt≥100E+9/L ; Neutrophils≥1.5E+9/L ; ALT AST ≤ triple normal upper limit ; TBIL ≤ 1.5 time normal upper limit ; Creatinine ≤ 1.5 time normal upper limit . The patient cancer time history cancer except controlled skin basal cell carcinoma skin squamous cell carcinoma carcinoma situ cervix uterus ; The patient active infection suitable chemotherapy ; The patient severe noncancerous disease . The patient bilateral breast cancer multifocal breast cancer inflammatory breast cancer . The patient history previous treatment mTOR inhibitor . The patient undergoing current administration anticancer therapy , attend clinical trial . The patient special condition understand write informed consent , demented hawkish . The patient allergic history contraindication interventional drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>